Mayzent (Siponimod)
siponimod 2 mg tablet, 28 · ORAL · PBS code 12158X
STREAMLINEDWhat it costs
AU$1955.38 PBS-determined price per 28 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2020-11-01.
- • Repeats: 5.
- • PBS program: GE.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Multiple sclerosis
Initial treatment
The condition must be/have previously been diagnosed as clinically definite relapsing-remitting multiple sclerosis by magnetic resonance imaging of at least one of the brain/spinal cord; or
The condition must be/have previously been diagnosed as clinically definite relapsing-remitting multiple sclerosis supported by written certification, which is documented in the patient's medical records, from a radiologist that a magnetic resonance imaging scan is contraindicated because of the risk of physical (not psychological) injury to the patient; AND
The treatment must be the sole PBS-subsidised disease modifying therapy for this condition; AND
Patient must be ambulatory, with/without assistance/support; AND
Patient must have mild disability in at least 3 functional systems; or
Patient must have moderate disability in at least 1 functional system; AND
Must be treated by a medical practitioner; or
Must be treated by a nurse practitioner in consultation with a specialist physician.
Functional systems referred to in this restriction are the: visual, brain stem, pyramidal, cerebellar, sensory, bowel/bladder and cerebral/cognitive systems.
Select a dose and pack size appropriate for the patient's CYP2C9 metabolising enzyme status.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Multiple sclerosis
Continuing treatment (including recommencement of treatment)
The treatment must be the sole PBS-subsidised disease modifying therapy for this condition; AND
Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND
Patient must not show continuing progression of disability while on treatment with this drug; AND
Patient must be ambulatory, with/without assistance/support; AND
Patient must have demonstrated compliance with, and an ability to tolerate this therapy; AND
Must be treated by a medical practitioner; or
Must be treated by a nurse practitioner in consultation with a specialist physician.
Sponsor: Novartis Pharmaceuticals Australia Pty Limited ABN 18 004 244 160
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.